Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Frankfurt - Delayed Quote EUR

Exelixis, Inc. (EX9.F)

Compare

37.01

-0.82

(-2.17%)

As of 12:39:14 PM GMT+1. Market Open.

Exploring 3 High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has experienced a 2.5% drop, yet it remains up by 13% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks involves examining companies that demonstrate strong potential for expansion and innovation amidst these dynamic market conditions.

Simply Wall St. 5 hours ago

WAY

EXEL

TGTX
Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now?

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other best immunology stocks to buy now. The Growing Market for Immune System Treatments Immunology is a rapidly advancing field with significant potential for growth, […]

Insider Monkey 2 days ago

EXEL
Exelixis focuses on future growth despite COSMIC-313 trial challenges

The final result of the COSMIC-313 trial is not the only disappointment for Exelixis.

Pharmaceutical Technology 4 days ago

EXEL
Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors have been highlighted in this Screen of The Week article.

Zacks 6 days ago

SYF-PB

GILD

EXEL
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

ALAMEDA, Calif., February 25, 2025--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March:

Business Wire 6 days ago

EXEL
Analysts Give The Green Light To Two Stocks With Brighter Outlook Than Even Nvidia

Investor's Business Daily's stock screener for companies with rising profit estimates has plenty of names on the list, but two seem to be weathering the recent market troubles better than most others — Carpenter Technology and Exelixis. Carpenter Technology stock recently broke out of a cup base with a buy point of 198.24. Carpenter Technology stock holds a Composite Rating and Relative Strength Rating of 97 with an EPS Rating of 81.

Investor's Business Daily 6 days ago

CRS

EXEL
EXEL or TECH: Which Is the Better Value Stock Right Now?

EXEL vs. TECH: Which Stock Is the Better Value Option?

Zacks 7 days ago

EXEL
Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolio’s Top Stock Picks

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other Renaissance Technologies portfolio’s top stock picks. The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its investment programs. […]

Insider Monkey 8 days ago

EXEL
Why Exelixis Stock Trounced the Market on Thursday

Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to push its shares 5% higher on the day. After market close on Thursday, Exelixis announced that it will launch a new share repurchase program, authorized for up to $500 million worth of its common stock before this coming Dec. 31.

Motley Fool 10 days ago

EXEL
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

On Friday, Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans to complete the $500 million stock repurchase program, announced in August 2024, in the second quarter of 2025 and commence stock repurchases under the newly authorized stock repurchase program thereafter. As of the end of fiscal year 2024, Exelixis has returned over $1.2 billion to shareholders through these programs. Earlier thi

Benzinga 10 days ago

EXEL
Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point

Exelixis, Inc. ( NASDAQ:EXEL ) recently posted some strong earnings, and the market responded positively. We did some...

Simply Wall St. 11 days ago

EXEL
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

ALAMEDA, Calif., February 20, 2025--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 million of the company’s common stock before December 31, 2025.

Business Wire 11 days ago

EXEL
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"

Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.

Zacks 11 days ago

EXEL
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 12 days ago

EXEL
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?

EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth.

Zacks 14 days ago

EXEL
International Markets and Exelixis (EXEL): A Deep Dive for Investors

Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Zacks 15 days ago

EXEL
Five-year results see Exelixis’ RCC therapy extending overall survival

Studied in combination with Opdivo, Cabometyx saw RCC patients surviving 11 months longer than Sunitinib patients.

Clinical Trials Arena 15 days ago

EXEL

GLDAF
Exelixis Full Year 2024 Earnings: EPS Beats Expectations

Exelixis ( NASDAQ:EXEL ) Full Year 2024 Results Key Financial Results Revenue: US$2.17b (up 19% from FY 2023). Net...

Simply Wall St. 16 days ago

EXEL
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

ALAMEDA, Calif., February 15, 2025--Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC). After more than five years of follow-up, the findings demonstrated that efficacy benefits with CABOMETYX in combination with Opdivo were sustained long term. These results, including subgr

Business Wire 17 days ago

EXEL
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 18 days ago

EXEL

Performance Overview

Return	EX9.F	S&P 500
YTD	+15.51%	-2.44%
1-Year	+82.50%	+11.83%
3-Year	+93.57%	+32.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Exelixis, Inc. (EX9.F)

Exploring 3 High Growth Tech Stocks In The US Market

Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now?

Exelixis focuses on future growth despite COSMIC-313 trial challenges

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

Analysts Give The Green Light To Two Stocks With Brighter Outlook Than Even Nvidia

EXEL or TECH: Which Is the Better Value Stock Right Now?

Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolio’s Top Stock Picks

Why Exelixis Stock Trounced the Market on Thursday

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?

International Markets and Exelixis (EXEL): A Deep Dive for Investors

Five-year results see Exelixis’ RCC therapy extending overall survival

Exelixis Full Year 2024 Earnings: EPS Beats Expectations

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Performance Overview